Is there a detrimental effect of waiting for radiotherapy for patients with localized prostate cancer?

Am J Clin Oncol. 2006 Oct;29(5):463-7. doi: 10.1097/01.coc.0000225919.35003.88.

Abstract

Objective: To evaluate a possible deleterious effect of waiting time to radiotherapy on the biochemical relapse (BR) of patients with localized prostate cancer.

Patients and methods: Patients included in this retrospective study had localized prostate adenocarcinoma treated with external-beam irradiation alone. Waiting time was defined as the interval between the first consultation and the first radiation treatment. BR was defined as 3 consecutive rises of prostatic specific antigen (PSA). Patients were split into 3 groups of waiting time: group A were treated within 40 days; group B waited 41 to 80 days; group C waited >80 days to receive radiotherapy. The effect of waiting on BR was estimated by the Kaplan-Meier method. Multivariate Cox proportional hazards modeling was adjusted for known prognostic factors.

Results: There were 289 patients who participated in the analysis. Median follow-up time was 6.1 year. Overall BR rate was 44% at 5 years. The median waiting time increased over the study period from 26 days in 1992 to 123 days in 2000. In adjusted multivariate analysis there was a nonsignificant higher risk of BR with waiting for 41 to 80 days (hazard ratio [HR] = 0.8; 95% confidence interval [CI] = 0.3-1.6) and for >80 days (HR = 0.6; 95% CI = 0.2-1.5) when compared with patients treated within 40 days after consultation.

Conclusion: Delaying the start of radiotherapy showed little effect on the rate of BR in the group of 288 prostate cancer patients analyzed in this study.

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / radiotherapy
  • Aged
  • Aged, 80 and over
  • Humans
  • Male
  • Middle Aged
  • Patient Selection
  • Proportional Hazards Models
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / radiotherapy*
  • Radiotherapy, High-Energy
  • Retrospective Studies
  • Survival Analysis
  • Time Factors

Substances

  • Prostate-Specific Antigen